SEC Form SC 13G filed
$HCXY
Save time and jump to the most important pieces.
Convertible Unsecured Notes due 2028 Initially Assigned a BBB+ by Kroll Bond Rating Agency Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), today announced that it has closed a private offering of $287.5 million aggregate principal amount of its 4.750% Convertible Unsecured Notes due 2028 (the "Convertible Notes"), which amount includes the additional $37.5 million aggregate principal amount of Convertible Notes issued pursuant to the initial purchasers' exercise in full of its overallotment option. The Convertible Notes were sold only to qualified institutional buyers (as defined in the Securities Act of 1933, as amended (the "Securities Act")) pursuant to Rule 144A under
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Morningstar DBRS ("DBRS") has upgraded Hercules' investment grade credit and corporate rating to BBB (high) from BBB with a trend revision from Positive to Stable, as well as its underlying analysis. "We are very pleased that DBRS has upgraded our investment grade credit and corporate rating to BBB (high) with a revised outlook to stable," stated Seth Meyer, chief financial officer of Hercules. "This
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), today announced that it has agreed to sell to the initial purchasers in a private offering, $250.0 million aggregate principal amount of its 4.75% Convertible Unsecured Notes due 2028 (the "Convertible Notes"). The Company also has granted the initial purchasers an option to purchase up to an additional $37.5 million principal amount of the Convertible Notes to cover overallotments, if any. The Convertible Notes will be offered only to qualified institutional buyers (as defined in the Securities Act of 1933, as amended (the "Securities Act")) pursuant to Rule 144A under the Securities Act. The closing of the transaction is su
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
Record Full-Year 2024 Total Investment Income of $493.6 Million, an Increase of 7.1% Year-over-Year Record Full-Year 2024 Net Investment Income "NII" of $325.8 Million, an Increase of 7.2% Year-over-Year Record Full-Year 2024 Gross Fundings of $1.81 Billion, an Increase of 13.0% Year-over-Year Q4 2024 NII of $81.1 Million, or $0.49 per Share, provides 123% Coverage of the Base Cash Distribution Q4 2024 Total Gross Debt and Equity Commitments of $619.5 Million Q4 2024 Total Gross Fundings of $468.5 Million Conservative Balance Sheet Management with Net GAAP Leverage of 83.9% and Net Regulatory Leverage of 69.9% Inclusive of the Adviser Funds Managed by Hercules Adviser LLC, its
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its fourth quarter and full-year 2024 financial results conference call for Thursday, February 13, 2025, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. To participate via telephone, please register here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can b
Record Q3 2024 Total Investment Income of $125.2 Million, an Increase of 7.3% Year-over-Year Q3 2024 Net Investment Income "NII" of $83.2 Million, or $0.51 per Share, an Increase of 8.3% Year-over-Year Q3 2024 NII Provides 128% Coverage of the Base Cash Distribution Q3 2024 Total Gross Debt and Equity Commitments of $430.7 Million Q3 2024 Total Gross Fundings of $272.0 Million Conservative Balance Sheet Management with Net GAAP Leverage of 92.5% and Net Regulatory Leverage of 83.0% Undistributed Earnings Spillover of $152.1 Million, or $0.94(1) per Ending Shares Outstanding Approximately $4.6 Billion of Assets Under Management, an Increase of 10.9% Year-over-Year(2) Hercules Capital
SC 13G - Hercules Capital, Inc. (0001280784) (Subject)
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that DeAnne Aguirre was appointed to serve as an independent member of its board of directors, effective June 23, 2022. Ms. Aguirre is an experienced corporate executive and Board Director with more than 30 years in senior leadership managing large and complex domestic and international business units. Ms. Aguirre will serve on the Nominating and Corporate Governance Committee. "As we continue to expand o
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Pam Randhawa was appointed to serve as a member of its board of directors, effective November 1, 2021. Ms. Randhawa is a thought leader within the life sciences sector and an experienced industry executive, with more than 20 years of experience leading public and private companies, ranging from biotech, healthcare and sustainable solutions, through their various stages of growth. Ms. Randhawa will ser